As of Q4'25, Eli Lilly (LLY) reported a gross margin of 85.1%, an operating margin of 45.5%, and a net profit margin of 34.4%. These figures represent the highest levels recorded in the observed period from Q1'23 to Q4'25, highlighting strong profitability at the end of the timeframe. Throughout the period, gross margin showed a steady upward trend, rising from 76.6% in Q1'23 to 85.1% in Q4'25. Operating and net profit margins were more volatile, with notable dips in Q3'23 and Q3'24—particularly a negative net margin in Q3'23—before rebounding sharply. Both margins reached new highs by Q4'25, indicating improved operational efficiency and profitability despite interim fluctuations.